Abbott collaborates with Velcera to market pain management item for pets Abbott announced today they possess partnered with Velcera, Inc., a specialty pharmaceutical company focused on pet health, to advertise the first canine discomfort management product delivered in a transmucosal mist type. In clinical trials Currently, the product combines the proven pain medication meloxicam, a non-steroidal anti-inflammatory drug with Velcera’s patented Promist technology, and has been licensed for pain management in canines globally Ici . Abbott Animal Health is dedicated to bringing top quality and innovative remedies to veterinarians and their customers, said Lynn Bromstedt, divisional vice president, Abbott Pet Health.
Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia The U.S.D, vice president, Global Pharmaceutical Clinical Development, Abbott.’ The National Cholesterol Education Program treatment recommendations recommend concern of the use of a fibrate with a statin in individuals with triglycerides at or above 200 mg/dL who are at LDL cholesterol goal, but not at non-HDL cholesterol goal. The suggestion of the Endocrinologic and Metabolic Medicines Advisory Committee will be looked at by the FDA in its decision-making process on fenofibric acid.